Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1034-1042

  Kozlowska H ^a   Baranowska, M ^a   Schlicker, E ^b   Kozlowski M ^a   Laudanski J ^a   Malinowska, B ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cannabidiol; Endothelial cannabinoid receptor; Human pulmonary artery; K Ca channels; O 1918; Virodhamine

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; APAMIN; ARACHIDONIC ACID; CALCIUM ACTIVATED POTASSIUM CHANNEL; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAZEPINE; CHARYBDOTOXIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; O 1918; POTASSIUM CHLORIDE; PROSTAGLANDIN SYNTHASE; PROSTANOID; RIMONABANT; SEROTONIN; UNCLASSIFIED DRUG; VIRODHAMINE;

ADULT; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY TONE; ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROLYSIS; DRUG MECHANISM; ENZYME MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

ARACHIDONIC ACID; ARACHIDONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; POTASSIUM CHLORIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PULMONARY ARTERY; RECEPTORS, CANNABINOID; SEROTONIN; VASODILATION;

EID: 56749152412     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.371     Document Type: Article

References (33)

1. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM et al. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145.
2. De Petrocellis L, Cascio MG, Di Marzo V (2004). The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141: 765-774.
3. Dempsie Y, MacLean MR (2008). Pulmonary hypertension: therapeutic targets within the serotonin system. Br J Pharmacol 155: 455-462.
4. Di Marzo V, De Petrocellis L, Bisogno T (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Pertwee RG (ed). Cannabinoids, Handbook of Experimental Pharmacology, vol 168, Springer: Berlin, Heidelberg, New York. pp 147-185.
5. Fernández-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutiérrez ML et al. (2004). Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 24: 477-483.
6. Fleming I, Schermer B, Popp R, Busse R (1999). Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126: 949-960.
7. Grainger J, Boachie-Ansah G (2001). Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134: 1003-1012.
8. Ho WS, Hiley CR (2003). Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138: 1320-1332.
9. Ho WS, Hiley CR (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 56: 869-875.
10. Ho WS, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150: 641-651.
11. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
12. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
13. Jones RT (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol 42 (11 Suppl): 58S-63S.
14. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR (2002). The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women. Br J Pharmacol 136: 1085-1088.
15. Kozłowska H, Baranowska M, Schlicker E, Kozłowski M, Laudañski J, Malinowska B (2007). Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 25: 2240-2248.
16. 2. Mol Pharmacol 73: 441-450.
17. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Bátkai S et al. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103: 2428-2433.
18. Moncada S, Higgs EA (2006). The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147: S193-S201.
19. Movahed P, Evilevitch V, Andersson TL, Jonsson BA, Wollmer P, Zygmunt PM et al. (2005). Vascular effects of anandamide and N-acylvanillylamines in the human and skin microcirculation. Br J Pharmacol 146: 171-179.
20. Naeije R, Huez S (2007). Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 8: 2247-2265.
21. Offertáler L, Mo FM, Bátkai S, Begg M, Razdan RK, Martin BR et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
22. O'Sullivan SE, Kendall DA, Randall MD (2004). Heterogeneity in the mechanisms of vasorelaxation to anandamide in conduit rat mesenteric arteries. Br J Pharmacol 142: 435-442.
23. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
24. Pertwee RG (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152: 984-986.
25. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020-1024.
26. 1 cannabinoid receptor. Am J Physiol 274: H375-H381.
27. Randall MD, Kendall DA, O'Sullivan S (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26.
28. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
29. Steffens M, Schulze-Bonhage A, Surgers R, Feuerstein TJ (2005). Fatty acid amidohydrolase in human neocortex-activity in epileptic and non-epileptic brain tissue and inhibition by putative endocannabinoids. Neurosci Lett 385: 13-17.
30. 2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
31. Wagner JA, Varga K, Járai Z, Kunos G (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
32. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M et al. (2001). Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294: 73-82.
33. 2 receptor linked to phosholipase C in calf pulmonary endothelial cells. Br J Pharmacol 140: 1351-1362.